Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Interest Expenses (2024)

Kairos Pharma (KAPA) has disclosed Interest Expenses for 1 consecutive years, with $105000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Interest Expenses changed N/A year-over-year to $105000.0, compared with a TTM value of $642000.0 through Jun 2025, changed N/A, and an annual FY2024 reading of $670000.0, up 1495.24% over the prior year.
  • Interest Expenses was $105000.0 for Q4 2024 at Kairos Pharma, down from $537000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $537000.0 in Q3 2024 and bottomed at $12000.0 in Q2 2024.